

Pm to pm IOP control



Provides
superior clinical
outcomes as
first-line
therapy¹

Proven long
term safety profile²
and **higher patient**
persistence³

Associated
with least
side-effects and
extra clinical
visits amongst
the 3 PGA⁴

References

1. Eur J Ophthalmol.2003;13 (4):S30-43
2. Eur J Ophthalmol.2008;18(3):408-16
3. Clinical ophthalmology.2010;4:261-267
4. http://www.pharmscope.com/content/glaucoma_management.pdf. Last accessed 5th March 2013.

3PGAs - latanoprost 0.005%, bimatoprost 0.03% & travoprost 0.004%

